The foundation’s giving is narrowly focused and programmatic: virtually all recorded funding ($7.88 billion across three entries) is devoted to providing pharmaceutical products to needy patients. Grants are in-kind/medication assistance rather than broad general operating support, reflecting a single, consistent patient-assistance mission tied to the company’s products. This giving pattern suggests the foundation operates primarily as a corporate patient assistance program rather than a diversified grantmaker.
Very large, concentrated awards delivered as in-kind pharmaceutical product assistance to patient beneficiaries; few distinct grants focused on one programmatic purpose
Notable grantees: Various Needy Patients (patient assistance recipients)
$7.9B
$60.6M
$992.1M
$1B
Most grants fall between $2.9B and $4B, with a median of $3.5B.
25th Percentile
$2.9B
Median
$3.5B
75th Percentile
$4B
About 100% of grants go to recipients in NJ.
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| VARIOUS NEEDY PATIENTS | NEW BRUNSWICK, NJ | $965,733,938 | 2025 | PHARMACEUTICAL PRODUCTS TO NEEDY PATIENTS |
| VARIOUS NEEDY PATIENTS | NEW BRUNSWICK, NJ | $2,301,799,470 | 2024 | PHARMACEUTICAL PRODUCTS TO NEEDY PATIENTS |
| VARIOUS NEEDY PATIENTS | NEW BRUNSWICK, NJ | $4,609,834,188 | 2023 | PHARMACEUTICAL PRODUCTS TO NEEDY PATIENTS |
VARIOUS NEEDY PATIENTS
$965,733,938PHARMACEUTICAL PRODUCTS TO NEEDY PATIENTS
VARIOUS NEEDY PATIENTS
$2,301,799,470PHARMACEUTICAL PRODUCTS TO NEEDY PATIENTS
VARIOUS NEEDY PATIENTS
$4,609,834,188PHARMACEUTICAL PRODUCTS TO NEEDY PATIENTS